Resilience Fund: Strand 2 to support Health and Lifesciences II Project -103944

复原力基金：支持健康与生命科学 II 项目的第 2 部分 -103944

• 批准号: 10024790
• 金额: $ 12.49万
• 依托单位: HIGHLAND BIOSCIENCES LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10024790
• 关键词: Resilience; Fund; Strand; support; Health

Traumatic injuries are a major unmet clinical need and the leading cause of death and disability among young people around the world. Trauma treatment and management is very complex, costly and resource-intense. It is a fast-moving environment where clinicians constantly seek the best treatment to manage and stabilise very sick patients. In these patients, blood loss causes usual levels of clotting factors to be deranged leading to coagulopathy. This defective clotting processes results in continued uncontrolled bleeding which has a high risk of mortality. This collaborative research project -- with Highland Biosciences Limited (HBL), the NIHR London In-Vitro Diagnostic Co-operative (LIVDC), Imperial College Healthcare NHS Trust, University of Sussex and University Hospitals Sussex NHS Foundation Trust - will develop new biosensor product technology. The new device will guide the selection of the best treatment and management regime for trauma patients by bringing results of a patient's clotting status to the patient's bedside within a few minutes and reduce the need for and number of blood transfusions in all but the most severely affected patients.

创伤性损伤是一个未得到满足的主要临床需求，也是世界各地年轻人死亡和残疾的主要原因。创伤治疗和管理非常复杂、昂贵和资源密集。这是一个快速发展的环境，临床医生不断寻求最佳治疗方法来管理和稳定病情严重的患者。在这些患者中，失血导致凝血因子的正常水平紊乱，导致凝血障碍。这种有缺陷的凝血过程导致持续的不受控制的出血，这具有高死亡风险。这个合作研究项目-与高地生物科学有限公司（HBL），NIHR伦敦体外诊断合作（LIVDC），帝国理工学院医疗保健NHS信托，苏塞克斯大学和苏塞克斯大学医院NHS基金会信托-将开发新的生物传感器产品技术。新设备将指导创伤患者选择最佳治疗和管理方案，在几分钟内将患者凝血状态的结果送到患者床边，并减少除受影响最严重的患者外的所有患者的输血需求和输血次数。